ASH 2020 | Myeloma: lenalidomide maintenance therapy
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, FL, discusses the results of a Phase II study of continuous lenalidomide maintenance therapy in multiple myeloma, and how it impacts measurable residual disease (MRD) negativity. The results highlighted the importance of MRD status in relation to PFS, as it was the most impactful variable at each landmark. The study supports the use of maintenance therapy and MRD tracking in clinical management. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consultancy: Adaptive, Amgen, Janssen, Glenmark, Celgene, Binding Site, BMS, Cellectis, Juno, Pfizer
Honoraria: Adaptive, Amgen, Janssen, Glenmark, Celgene, Binding Site, BMS, Cellectis, Juno, Pfizer
Research Funding: Amgen, Janssen, Takeda, Glenmark, Celgene, Seattle Genetics, Karyopharma
Independent Data Monitoring Committees for clinical trials: Janssen, Takeda
Other: Merck
